



# Supplementary Material: NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial

Thomas Geyer, Johannes Rübenthaler, Marianna Alunni-Fabbroni, Regina Schinner, Sabine Weber, Julia Mayerle, Eric Schiffer, Sebastian Höckner, Peter Malfertheiner and Jens Ricke



**Figure S1.** Kaplan–Meier survival analysis of patients with an early HCC who received treatment with sorafenib (blue) and patients with an early HCC who received treatment without sorafenib (red). The p-value was calculated using the log-rank test. CI = confidence interval; HCC = hepa-tocellular carcinoma.



**Figure S2.** Kaplan–Meier survival analysis of patients with an advanced HCC who received treatment with SIRT (blue) and patients with an advanced HCC who received treatment without SIRT (red). The  $p$ -value was calculated using the log-rank test. CI = confidence interval; HCC = hepatocellular carcinoma; SIRT = selective internal radiation therapy.